IGM Biosciences Revises its Collaboration with Sanofi
Shots:
- IGM Biosciences and Sanofi have revised the previous exclusive worldwide agreement to solely develop 3 immunology/inflammation targets. IGM will keep the worldwide rights to its technology related to the oncology targets nominated by Sanofi
- Under the agreement, IGM will be responsible for the research & development of the targets covering the cost of P-I study for up to two constructs per target. Sanofi will handle further development & commercialization activities & related costs
- IGM is entitled to receive a total of ~$1,065M as development, regulatory & commercial milestones per target plus tiered high single-digit to low-teen sales-based royalties
Ref: IGM Biosciences | Image: IGM Biosciences
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
